ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced its intention to offer, subject to market and other conditions, $300 million principal amount of convertible senior notes due 2021 (the "Notes") pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission ("SEC") today. Acorda also intends to grant the underwriter an option to purchase up to an additional $45 million principal amount of Notes to cover over-allotments, if any.
Help employers find you! Check out all the jobs and post your resume.
